Loading
Adding a FLT3 blocker to standard chemotherapy is the proven way to improve survival in FLT3-mutated AML.
This combination adds a FLT3 inhibitor, quizartinib or midostaurin, to intensive cytarabine and anthracycline induction chemotherapy, the 7+3 regimen, in FLT3-mutated acute myeloid leukaemia. Chemotherapy debulks the leukaemia while FLT3 inhibition removes the proliferative driver and suppresses the resistant subclone that would otherwise cause relapse. Two positive phase 3 trials with different molecules, RATIFY with midostaurin and QuANTUM-First with quizartinib, both improved overall survival, and quizartinib is continued as maintenance after induction. Maintenance with gilteritinib after transplant, tested in MORPHO, adds further protection in patients who are MRD-positive.
Shares QuANTUM-First, RATIFY (CALGB 10603), QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML, FLT3.
Shares Quizartinib, Midostaurin, Gilteritinib, FLT3.
Shares Quizartinib, QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML, Midostaurin, Gilteritinib.
Shares Quizartinib, Midostaurin, Gilteritinib, FLT3.
Shares RATIFY (CALGB 10603), Midostaurin, FLT3-mutated acute myeloid leukaemia.
Shares RATIFY (CALGB 10603), FLT3, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Quizartinib, Midostaurin, Gilteritinib, FLT3.
Shares Midostaurin, FLT3, Acute myeloid leukaemia.